5.Conclusion
The Fingolimod plus standard
treatment group resulted in more ischemic penumbra rescue and improved
clinical function than the standard
treatment. A higher
proportion of patients with MRS
0–1 at 90 days in the fingolimod plus standard group than
the standard treatment
group. Fingolimod plus standard
treatment showed a decrease in
NIHSS score at 24 hours compared with standard treatment. However, the
trend did not persist through 7 days, and there was no statistically
significant decrease in NIHSS scores
at 7 days compared to the standard
treatment group. Still, there was a statistically significant decrease
at 90 days. The fingolimod plus
standard treatment group showed less
lesion enlargement at 24 hours
than the standard treatment group. The trend continued for 7
days. There was
no significant difference in the
incidence of complications and adverse events between the standard
treatment group and fingolimod
plus standard treatment group. Our study
shows that it is feasible to use
fingolimod to treat AIS.
Abbreviations: AIS: Acute ischemic stroke, PRISMA: Preferred
Reporting Items for Systemic Reviews and Meta-Analysis, MRS: Modified
Rankin Scale, MD: mean difference, RCTs: Randomized controlled
trials,tPA: tissue plasminogen activator, BBB: blood-brain barrier,
MeSH: Medical Subject Heading, NIHSS: National Institutes of Health
Stroke Scale, CI: confidence interval, RR: risk ratio, SAEs: serious
adverse events, AEs: adverse events, S1PR: sphingosine-1-phosphate
receptors, MS: multiple sclerosis.CNS: Central nervous system, PB: Peng
Bai, NL: Na Li, JY: Jun Yuan, RZ: Runxiu Zhu, PW: Ping Wang, FJ: Feng
Jiang, JZ: Jin Zhen, YY: Yuan Yao, CZ: Chenhui Zhao, ZL: Zihong Liang,
MW: Meiling Wang, BL: Bin Liu, ML: Min Li.